ARA 290 (Cibinetide): Research Guide & Chemical Profile

ARA 290, also known by its INN designation cibinetide, is a synthetic 11-amino-acid peptide derived from the B helix of erythropoietin (EPO). Unlike EPO itself, ARA 290 does not bind the classical homodimeric EPO receptor (EPOR/EPOR) and therefore exerts no erythropoietic or thrombopoietic activity. Instead, it selectively targets the innate repair receptor (IRR), a heteromeric complex composed of EPOR and the beta common receptor (betacR/CD131). This receptor selectivity allows ARA 290 to activate tissue-protective and anti-inflammatory signaling pathways without the hematological side effects associated with EPO administration.

ARA 290 has the sequence pyroglutamate-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser with a molecular weight of 1,257.4 Da. The N-terminal pyroglutamate residue is a post-translational modification that protects against aminopeptidase degradation, contributing to the peptide stability profile. The sequence corresponds to amino acids 58-68 of the EPO B helix, a region previously identified through structure-activity relationship studies as critical for tissue-protective signaling via the IRR.

The peptide is amphipathic in its helical conformation, with hydrophobic residues (Leu-4, Ala-7, Leu-8) oriented on one face and polar residues (Glu-2, Gln-3, Glu-5, Arg-6, Asn-9, Ser-10, Ser-11) on the opposing face. This amphipathic character is essential for receptor binding — alanine substitution of the hydrophobic face residues abolishes IRR activation in reporter gene assays.

The innate repair receptor is a heterocomplex of EPOR and betacR that is upregulated in tissues under stress, injury, or inflammation. Unlike the classical EPOR homodimer (which mediates erythropoiesis and requires picomolar EPO concentrations), the IRR is activated at nanomolar concentrations and triggers distinct downstream signaling cascades. ARA 290 binding to the IRR activates JAK2/STAT5 signaling with a different kinetic profile than EPO — producing sustained, low-amplitude activation rather than the transient, high-amplitude phosphorylation seen with EPO.

Downstream of JAK2, ARA 290-IRR signaling engages anti-apoptotic (Bcl-xL upregulation), anti-inflammatory (NF-kappaB suppression), and metabolic (AMPK activation) pathways. In macrophage polarization assays, ARA 290 shifts the balance from M1 (pro-inflammatory) toward M2 (tissue-repair) phenotypes, as measured by decreased iNOS expression and increased arginase-1 and CD206 expression.

The rational design of ARA 290 was based on the observation that EPO exhibits tissue-protective effects independent of its erythropoietic function. However, clinical use of EPO for tissue protection was limited by dangerous side effects including polycythemia, thrombosis, and hypertension. Structure-activity studies identified the B helix region as the minimal domain required for IRR binding while lacking affinity for the EPOR homodimer.

In preclinical hematology studies, ARA 290 administered at doses up to 100 ug/kg daily for 28 days produced no measurable change in reticulocyte count, hemoglobin, or hematocrit in rodent models. This confirmed the complete dissociation of tissue-protective activity from erythropoietic stimulation, validating the design rationale.

ARA 290 has been investigated in small fiber neuropathy (SFN) in multiple clinical studies. In a Phase 2 randomized controlled trial of patients with sarcoidosis-associated SFN, subcutaneous ARA 290 (4 mg daily for 28 days) produced statistically significant improvements in corneal nerve fiber density as measured by corneal confocal microscopy — a validated surrogate endpoint for small fiber regeneration. Treatment subjects showed a mean increase of 2.3 fibers/mm compared to a decrease of 0.6 fibers/mm in the placebo group (p = 0.02).

Additional neurological endpoints included improvement in intraepidermal nerve fiber density (IENFD) on skin biopsy and reduction in neuropathic pain scores on the Small Fiber Neuropathy Screening List (SFNSL). These findings suggest that ARA 290 may promote axonal regeneration of small sensory fibers, an effect attributed to IRR-mediated activation of neuronal survival pathways including PI3K/Akt and MAPK/ERK.

Sarcoidosis, a systemic granulomatous disease, has been a primary clinical research focus for ARA 290. Phase 2 trials conducted in the Netherlands enrolled patients with chronic sarcoidosis and demonstrated that ARA 290 treatment reduced circulating inflammatory markers including TNF-alpha and IL-6 while improving patient-reported fatigue scores on the Fatigue Assessment Scale (FAS). The anti-inflammatory mechanism is attributed to IRR-mediated suppression of NF-kappaB signaling in activated macrophages within granulomas.

In open-label extension studies, patients receiving ARA 290 for up to 6 months showed sustained improvement in small fiber neuropathy symptoms and maintained reduction in inflammatory biomarkers. No significant safety concerns were identified, with injection site reactions being the most commonly reported adverse event.

Beyond neuropathy and sarcoidosis, ARA 290 has demonstrated anti-inflammatory activity in diverse preclinical models. In renal ischemia-reperfusion injury models, pre-treatment with ARA 290 reduced tubular necrosis scores by 45% and decreased serum creatinine by 38% compared to vehicle controls. In cardiac ischemia models, ARA 290 reduced infarct size by 30% when administered at the time of reperfusion, with the protective effect blocked by anti-betacR antibodies — confirming IRR dependence.

The peptide also demonstrates activity in metabolic inflammation models. In diabetic wound healing studies, ARA 290 accelerated wound closure in db/db mice (a genetic model of type 2 diabetes) by restoring macrophage function and promoting angiogenesis in the wound bed, effects that were impaired in the diabetic state due to chronic low-grade inflammation.

Research-grade ARA 290 is characterized by HPLC purity of 97% or higher, confirmed by reversed-phase C18 chromatography. Mass spectrometry should confirm the [M+H]+ ion at m/z 1,258.4. The presence of the N-terminal pyroglutamate must be verified, as the linear glutamine precursor (uncyclized form) has different biological activity. Certificates of Analysis should include amino acid analysis, peptide content determination, residual solvent and TFA content, and endotoxin testing for in vivo research applications.

• Brines M et al. (2008). Nonerythropoietic tissue-protective peptides derived from EPO. Mol Med, 14(7-8):419-426.
• Dahan A et al. (2013). ARA 290 improves neuropathy in sarcoidosis. Neurology, 80(18):1691-1697.
• Brines M, Bhatt DL et al. (2015). Cibinetide safety and efficacy. J Biol Chem, 290(22):14195-14203.
• Swartjes M et al. (2014). ARA 290 and small fiber neuropathy. Pain, 155(8):1577-1585.
• Heij L et al. (2012). Innate repair receptor signaling and tissue protection. Mol Med, 18:486-496.
• Brines M, Cerami A. (2012). The receptor that tames the innate immune response. Mol Med, 18:486-496.
• Dahan A et al. (2016). Phase 2 cibinetide trial in sarcoidosis-associated SFN. Pain, 157(6):1289-1296.
• Cerit M et al. (2020). Long-term effects of cibinetide in sarcoidosis. Respir Med, 172:106145.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism